M. Nakamura et al., RECOMBINANT HUMAN MEGAKARYOCYTE GROWTH AND DEVELOPMENT FACTOR ATTENUATES POSTBYPASS THROMBOCYTOPENIA, The Annals of thoracic surgery, 66(4), 1998, pp. 1216-1223
Citations number
25
Categorie Soggetti
Surgery,"Cardiac & Cardiovascular System","Respiratory System
Background. Cardiopulmonary bypass contributes to platelet loss and dy
sfunction by exposure to shear stresses, foreign surfaces, and hypothe
rmia. This study tested the hypothesis that pegylated recombinant huma
n megakaryocyte growth and development factor (PEG-rHuMGDF) accelerate
s recovery of the platelet population after hypothermic extracorporeal
circulation (HEC). Methods. In a blinded study, subcutaneous injectio
ns of drug or placebo were given to dogs daily for 3 days preoperative
ly (day 0, 1, and 2) with no drug on day 3. On day 4, the animal was p
repared for arteriovenous HEC. After heparinization, HEC was initiated
at 30 to 40 mt kg-l min-l. Hypothermic extracorporeal circulation (25
degrees C) was continued for 90 minutes. Results. Preoperative platel
et count (x10(3) platelets/mu L) did not differ from predrug count in
placebo (256 +/- 27 versus 255 +/- 20) or PEG-rHuMGDF (271 +/- 30 vers
us 291 +/- 38). During 60 minutes of HEC, the platelet count decreased
to similar to 10% of baseline in placebo (29 +/- 5) and PEG-rHuMGDF (
46 +/- 8), and recovered to similar to 70% of baseline after rewarming
(90 minutes of HEC: placebo, 185 +/- 17, versus PEG-rHuMGDF, 169 +/-
22). After HEC, platelet count was greater in PEG-rHuMGDF-treated anim
als (p < 0.05) without altering function (aggregation responses). With
in the first 6 hours after HEC, platelet count in PEG-rHuMGDF-treated
animals was rising and increased to 260 +/- 29 (p < 0.01), but was unc
hanged in placebo animals (186 +/- 21). Thereafter, platelet count in
placebo animals declined to a nadir of 124 +/- 15 (72 hours after HEC)
, whereas platelet count in PEG-rHuMGDF animals approximated the preop
erative value (>200) at all times. Conclusions. Appropriately timed pr
esurgical administration of PEG-rHuMGDF counteracts post-HEC relative
thrombocytopenia without increasing platelet population and enhancing
aggregation preoperatively or during extracorporeal circulation. (Ann
Thorac Surg 1998;66:1216-23) (C) 1998 by The Society of Thoracic Surge
ons.